CureVac posts early Phase 1 results for mRNA-based cancer vaccine

Nov. 11, 2022 11:10 AM ETCureVac N.V. (CVAC)PFE, BNTXBy: Dulan Lokuwithana, SA News Editor

Trump Reportedly Seeking Exclusive Access To Coronavirus Vaccine From German Biotech Firm CureVac

Matthias Hangst/Getty Images News

On Friday, German biotech CureVac N.V. (NASDAQ:CVAC) announced preliminary data from its Phase 1 study for CV8102, a messenger-RNA-based cancer vaccine undergoing studies as a single agent and in combination with PD1-antibodies.

The company said

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.